14 February 2025
Nuformix plc
("Nuformix" or the "Company")
Posting of Annual Report and Notice of Annual General Meeting
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual Financial Report for the year ended 30 September 2024 (the "Annual Financial Report 2024") and the 2025 Notice of Annual General Meeting ("AGM") are today being posted to its shareholders.
A full pdf version of the Annual Financial Report 2024 together with the Notice of AGM will shortly be available for download from the Company's website at: https://nuformix.com/document-center/
The AGM will be held on 20 March 2025 at 10.00 a.m. at the offices of Shakespeare Martineau, 6th floor, 60 Gracechurch Street, London, EC3V 0HR.
Enquiries:
| Nuformix plc Dr Daniel Gooding, Executive Director
| Via IFC Advisory |
| CMC Markets Douglas Crippen
| +44 (0) 20 3003 8632 |
| IFC Advisory Limited Tim Metcalfe Zach Cohen | +44 (0) 20 3934 6630 nuformix@investor-focus.co.uk |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.